Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences reported Q1 2026 revenue of $17 million, a decrease from $28 million in Q1 2025, with a net loss widening to $128 million. Arcus Biosciences and Gilead Sciences discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies due to futility. Gilead Sciences announced it would let certain option rights lapse in July 2026, narrowing its access to Arcus's early pipeline. Arcus has emphasized its strategic realignment around casdatifan, aiming to establish it as a foundational standard of care in kidney cancer. Analysts have maintained a "Buy" consensus for RCUS, with a mean price target of $34.

Demand for oncology drugs is generally less subject to seasonal fluctuations compared to treatments for acute seasonal illnesses. While the broader biotech market can experience seasonal downturns, there is no specific information indicating significant demand seasonality for Arcus Biosciences' specific product pipeline. The company's products are in clinical development, meaning direct product demand seasonality is not currently a primary factor.

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and therapies for inflammatory and autoimmune diseases. The company operates in the Biotechnology and Drug Discovery industry, developing next-generation cancer immunotherapies by targeting multiple immunosuppressive mechanisms. Its pipeline includes domvanalimab, quemliclustat, casdatifan, zimberelimab, etrumadenant, AB598, AB801, and an emerging I&I portfolio.

Arcus Biosciences is headquartered in Hayward, California, in the San Francisco Bay Area, where its discovery, translational, and clinical operations are centered. The company's research and development efforts are supported globally, with clinical trial operations extending across North America, Europe, and the Asia-Pacific region.

Arcus Biosciences maintains a reputation as a clinical-stage biopharmaceutical company focused on developing best-in-class cancer therapies through innovative combination approaches. The discontinuation of the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies could negatively affect its reputation. Gilead's decision to let certain option rights lapse may also be perceived negatively. The company's pivot to prioritize casdatifan highlights the setbacks in other pipeline areas.

Arcus Biosciences has a diverse ownership structure, including institutional, retail, and individual investors. As of May 2026, Arcus Biosciences has 215 institutional owners holding a total of 122,020,583 shares. Gilead Sciences Inc. is also the largest individual shareholder, owning 31.42 million shares, representing 25.07% of the company. Insider ownership is in the single digits.